- Home
- News
- us virgislands
- biopharmaceutical development
Refine by
Biopharmaceutical Development Articles & Analysis
325 news found
This is a transformative moment in our journey to deliver greater value to customers across the biopharmaceutical and clinical markets. Starting today we will be also unveiling a refreshed brand identity and logo across the merged organization that reflects our forward-looking vision and deep commitment to innovation. ...
Creative BioMart, a biotechnology company specializing in cell line development and protein production, has recently upgraded its GMP stable cell line development platform. This platform provides biopharmaceutical companies with a structured and regulatory-compliant approach to develop stable cell lines for therapeutic proteins, ...
(Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. ...
ByKalaris
They are also critical components in antibody-drug conjugate (ADC) linkers, facilitating targeted drug delivery, and in PROTAC linkers, enabling the development of novel protein degradation therapies. Their uniform molecular weight and high purity ensure consistent performance, making them a reliable choice for researchers and manufacturers. Monodispersed PEGs play a pivotal role ...
CD Genomics, a leading provider of high-throughput sequencing services, is at the forefront of this exciting development, empowering researchers to unlock the secrets of the lncRNA world through its state-of-the-art LncRNA Sequencing platform. ...
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA. As CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells are ...
(NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
(OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire ...
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. ...
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and more.ADCs ...
(Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
Biopharma PEG, a leading provider of innovative solutions for the pharmaceutical industry, is proud to announce an extensive inventory of monodispersed PEGs (Polyethylene Glycols) that cater to a wide range of applications, including Antibody Drug Conjugates (ADCs), PROTACs, drug delivery systems, and more. Our comprehensive collection includes mPEG36-NH2, NH2-PEG24-COOH, mPEG11-SPA, ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids. ...
Take antibody-drug conjugates, the commonly studied subject of XDCs, as an example, BOC Sciences has developed chemical or enzymatic approaches or combinations thereof to precisely modify specific amino acids to produce ADCs with accurate drug loading and predefined, controlled attachment sites. ...
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage ...
LOTTE BIOLOGICS and EXCELLGENE today announced the signing of a Memorandum of Understanding to collaborate in the biopharmaceutical Contract Development Organization (CDO) business. With this agreement, LOTTE BIOLOGICS will be able to proactively promote its CDO business by attracting a large number of customers ahead of its long-term strategy of expanding its ...
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of drugs to patients. Revolutionizing Biopharma manufacturing LenioBio develops efficient and sustainable technologies for protein expression. Company with a clear goal: To simplify protein production and accelerate the delivery of ...
With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. ...